A Systematic Evaluation of Antibody Modification and 89Zr-Radiolabeling for Optimized Immuno-PET

Immuno-PET using desferrioxamine (DFO)-conjugated zirconium-89 ([Zr-89]Zr4+)-labeled antibodies is a powerful tool used for predinical and clinical molecular imaging. However, a comprehensive study evaluating the variables involved in DFO-conjugation and Zr-89-radiolabeling of antibodies and their impact on the in vitro and in vivo behavior of the resulting radio-immunoconjugates has not been adequately performed. Here, we synthesized different DFO-conjugates of the HER2-targeting antibody (Ab)-trastuzumab, dubbed T5, T10, T20, T60, and T200-to indicate the molar equivalents of DFO used for bioconjugation. Next we radiolabeled the immunoconjugates with ([Zr-89]Zr4+) under a comprehensive set of reaction conditions including different buffers (PBS, chelexed-PBS, TRIS/ HCl, HEPES; +/- radioprotectants), different reaction volumes (0.1-1 mL), variable amounts of DFO-conjugated Ab (5, 25, 50 mu g), and radioactivity (0.2-1.0 mCi; 7.4-37 MBq). We evaluated the effects of these variables on radiochemical yield (RCY), molar activity (A(m))/specific activity (A(s)), immunoreactive fraction, and ultimately the in vivo biodistribution profile and tumor targeting ability of the trastuzumab radioimmunoconjugates. We show that increasing the degree of DFO conjugation to trastuzumab increased the RCY (similar to 90%) and A(m)/A(s) (similar to 194 MBq/nmol; 35 mCi/mg) but decreased the HER2-binding affinity (3.5x-4.6X) and the immunoreactive fraction of trastuzumab down to 50-64%, which translated to dramatically inferior in vivo performance of the radioimmunoconjugate. Cell-based immunoreactivity assays and standard binding affinity analyses using surface plasmon resonance (SPR) did not predict the poor in vivo performance of the most extreme T200 conjugate. However, SPR-based concentration free calibration analysis yielded active antibody concentration and was predictive of the in vivo trends. Positron emission tomography (PET) imaging and biodistribution studies in a HER2-positive xenograft model revealed activity concentrations of 38.7 +/- 3.8 %ID/g in the tumor and 6.3 +/- 4.1 %ID/g in the liver for ([Zr-89]Zr4+)-T5 (similar to 1.4 +/- 0.5 DFOs/Ab) at 120 h after injection of the radioimmunoconjugates. On the other hand, ([Zr-89]Zr4+)-T200 (10.9 +/- 0.7 DFOs/Ab) yielded 16.2 +/- 3.2 %ID/g in the tumor versus 27.5 +/- 4.1 %ID/g in the liver. Collectively, our findings suggest that synthesizing trastuzumab immunoconjugates bearing 1-3 DFOs per Ab (T5 and T10) combined with radiolabeling performed in low reaction volumes using Chelex treated PBS or HEPEs without a radioprotectant provided radioimmunoconjugates having high A(m)/A(s) (97 MBq/nmol; 17.5 +/- 2.2 mCi/mg), highly preserved immunoreactive fractions (86-93%), and favorable in vivo biodistribution profile with excellent tumor uptake.

Automated summary

Synthesizing trastuzumab immunoconjugates with 1-3 DFOs per Ab (T5 and T10) and radiolabeling in low reaction volumes using Chelex treated PBS or HEPEs without a radioprotectant resulted in radioimmunoconjugates with high molar activity/specific activity (97 MBq/nmol; 17.5 +/- 2.2 mCi/mg), preserved immunoreactive fractions (86-93%), and favorable in vivo biodistribution profile with excellent tumor uptake.